Lantheus Company Profile

What is the competitive landscape for LANTHEUS

LANTHEUS has seven approved drugs.

There are thirteen US patents protecting LANTHEUS drugs.

There are one hundred and thirty-five patent family members on LANTHEUS drugs in thirty-two countries and twenty-nine supplementary protection certificates in sixteen countries.

Summary for Lantheus

International Patents:	135
US Patents:	13
Tradenames:	8
Ingredients:	7
NDAs:	7

Drugs and US Patents for Lantheus

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lantheus Medcl	DEFINITY RT	perflutren	INJECTABLE;INTRAVENOUS	021064-002	Nov 17, 2020		RX	Yes	Yes	11,266,750
Lantheus Medcl	DEFINITY	perflutren	INJECTABLE;INTRAVENOUS	021064-001	Jul 31, 2001		RX	Yes	Yes	10,588,988
Lantheus Medcl	GALLIUM CITRATE GA 67	gallium citrate ga-67	INJECTABLE;INJECTION	017478-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Lantheus	NEURACEQ	florbetaben f-18	SOLUTION;INTRAVENOUS	204677-001	Mar 19, 2014		RX	Yes	Yes	7,807,135		Y	Y
Lantheus Medcl	DEFINITY RT	perflutren	INJECTABLE;INTRAVENOUS	021064-002	Nov 17, 2020		RX	Yes	Yes	9,789,210
Lantheus Medcl	DEFINITY RT	perflutren	INJECTABLE;INTRAVENOUS	021064-002	Nov 17, 2020		RX	Yes	Yes	10,588,988
Lantheus Medcl	DEFINITY	perflutren	INJECTABLE;INTRAVENOUS	021064-001	Jul 31, 2001		RX	Yes	Yes	9,789,210

Expired US Patents for Lantheus

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Lantheus Medcl	DEFINITY	perflutren	INJECTABLE;INTRAVENOUS	021064-001	Jul 31, 2001	5,769,080
Lantheus Medcl	ABLAVAR	gadofosveset trisodium	SOLUTION;INTRAVENOUS	021711-002	Dec 22, 2008	7,060,250
Lantheus Medcl	ABLAVAR	gadofosveset trisodium	SOLUTION;INTRAVENOUS	021711-002	Dec 22, 2008	7,011,815
Lantheus Medcl	ABLAVAR	gadofosveset trisodium	SOLUTION;INTRAVENOUS	021711-002	Dec 22, 2008	6,676,929
Lantheus Medcl	DEFINITY	perflutren	INJECTABLE;INTRAVENOUS	021064-001	Jul 31, 2001	6,146,657
Lantheus Medcl	DEFINITY	perflutren	INJECTABLE;INTRAVENOUS	021064-001	Jul 31, 2001	6,528,039
Lantheus Medcl	DEFINITY	perflutren	INJECTABLE;INTRAVENOUS	021064-001	Jul 31, 2001	5,527,521

International Patents for Lantheus Drugs

Country	Patent Number	Estimated Expiration
South Korea	20170098880
Taiwan	I745282
Singapore	11201810455X
Poland	2213652
Canada	3025580
Spain	2928401
Mexico	2022011694

Supplementary Protection Certificates for Lantheus Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2213652	PA2015005,C2213652	Lithuania		PRODUCT NAME: FLORBETABENAS (18F); REGISTRATION NO/DATE: EU/1/13/906/001 20140220
0806968	PA2007003,C0806968	Lithuania		PRODUCT NAME: GADOFOSVESETUM TRINATRICUM; REGISTRATION NO/DATE: EU/1/05/313/001, 2005 10 05 EU/1/05/313/002, 2005 10 05 EU/1/05/313/003, 2005 10 05 EU/1/05/313/004, 2005 10 05 EU/1/05/313/005, 2005 10 05 EU/1/05/313/006, 2006 10 05 EU/1/05/313/007, 2005 10 05 EU/1/05/313/008, 2005 10 05 EU/1/05/313/00 2005100
0712293	C300267	Netherlands		PRODUCT NAME: PERFLUTREN BEVATTENDE LIPIDE-MICROBOLLEN; REGISTRATION NO/DATE: EU/1/06/361/001 20060920
0712293	SPC/GB07/031	United Kingdom		PRODUCT NAME: PERFLUTREN-CONTAINING LIPID MICROSPHERES; REGISTERED: UK EU/1/06/361/001 20060920
2213652	15C0012	France		PRODUCT NAME: FLORBETABEN (18F); REGISTRATION NO/DATE: EU/1/13/906/001 20140224
2213652	92647	Luxembourg		PRODUCT NAME: FLORBETABEN (18F). FIRST REGISTRATION: 20140224
0806968	SPC/GB07/011	United Kingdom		PRODUCT NAME: GADOFOSVESET TRISODIUM; REGISTERED: UK EU/1/05/313/001 20051003; UK EU/1/05/313/002 20051003; UK EU/1/05/313/003 20051003; UK EU/1/05/313/004 20051003; UK EU/1/05/313/005 20051003; UK EU/1/05/313/006 20051003; UK EU/1/05/313/007 20051003; UK EU/1/05/313/008 20051003; UK EU/1/05/313/009 20051003

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Lantheus
• Lantheus Medcl
• Lantheus Medical